GB0819105D0 - Pyrrolo-pyrimidine compounds - Google Patents

Pyrrolo-pyrimidine compounds

Info

Publication number
GB0819105D0
GB0819105D0 GBGB0819105.8A GB0819105A GB0819105D0 GB 0819105 D0 GB0819105 D0 GB 0819105D0 GB 0819105 A GB0819105 A GB 0819105A GB 0819105 D0 GB0819105 D0 GB 0819105D0
Authority
GB
United Kingdom
Prior art keywords
pyrrolo
pyrimidine compounds
pyrimidine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0819105.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Priority to GBGB0819105.8A priority Critical patent/GB0819105D0/en
Publication of GB0819105D0 publication Critical patent/GB0819105D0/en
Priority to PCT/GB2009/002464 priority patent/WO2010043865A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0819105.8A 2008-10-17 2008-10-17 Pyrrolo-pyrimidine compounds Ceased GB0819105D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0819105.8A GB0819105D0 (en) 2008-10-17 2008-10-17 Pyrrolo-pyrimidine compounds
PCT/GB2009/002464 WO2010043865A1 (en) 2008-10-17 2009-10-15 Inhibitors of hsp90

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0819105.8A GB0819105D0 (en) 2008-10-17 2008-10-17 Pyrrolo-pyrimidine compounds

Publications (1)

Publication Number Publication Date
GB0819105D0 true GB0819105D0 (en) 2008-11-26

Family

ID=40097629

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0819105.8A Ceased GB0819105D0 (en) 2008-10-17 2008-10-17 Pyrrolo-pyrimidine compounds

Country Status (2)

Country Link
GB (1) GB0819105D0 (en)
WO (1) WO2010043865A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2331547T3 (en) 2008-08-22 2014-11-03 Novartis Ag Pyrrolopyrimidine Compounds as CDK Inhibitors
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CN103958510B (en) 2011-10-03 2016-10-19 北卡罗来纳大学教堂山分校 For treating the Pyrrolopyrimidine compounds of cancer
AU2013210403B2 (en) * 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
EP2852579A4 (en) 2012-05-22 2015-12-30 Univ North Carolina Pyrimidine compounds for the treatment of cancer
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina Pyrimidine compounds for the treatment of cancer
ES2819398T3 (en) 2013-07-18 2021-04-15 Taiho Pharmaceutical Co Ltd Therapeutic agent for cancer resistant to the FGFR inhibitor
EP3023100B1 (en) 2013-07-18 2019-03-13 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor
WO2015157128A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
MX2017012568A (en) 2015-03-31 2018-01-25 Taiho Pharmaceutical Co Ltd Crystal of 3,5-disubstituted benzene alkynyl compound.
AU2017226389B2 (en) 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
AU2019239404B2 (en) 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609509A2 (en) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp pharmaceutically acceptable compound or a polymorph, solvate, tautomer, enantiomer, prodrug or salt thereof, pharmaceutical composition, and, use of the pharmaceutically acceptable compound, polymorph, solvate, tautomer, enantiomer, prodrug or salt

Also Published As

Publication number Publication date
WO2010043865A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
GB0807862D0 (en) Compounds
GB0800035D0 (en) Compounds
GB0819105D0 (en) Pyrrolo-pyrimidine compounds
GB0804702D0 (en) Compounds
GB0809776D0 (en) Compounds
GB0807103D0 (en) Compounds
GB0800367D0 (en) Compounds
GB0807910D0 (en) Compounds
GB0801220D0 (en) Compounds
GB0819102D0 (en) Pyrrolo-pyrimidine compounds
GB0801265D0 (en) Compounds
GB0804064D0 (en) Compounds
GB0800338D0 (en) Compounds
GB0800961D0 (en) Compounds
GB0800841D0 (en) Compounds
GB0801596D0 (en) Compounds
GB0802191D0 (en) Compounds
GB0802192D0 (en) Compounds
GB0802231D0 (en) Compounds
GB0802586D0 (en) Compounds
GB0802587D0 (en) Compounds
GB0803495D0 (en) Compounds
GB0803496D0 (en) Compounds
GB0800455D0 (en) Compounds
GB0800454D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)